Cagrilintide (5mg) Dosage Protocol
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. Amylin is co-secreted with insulin and promotes satiety. It is being developed in combination with semaglutide (CagriSema).
Add 1.0 mL bacteriostatic water → 5 mg/mL
1.2-2.4 mg once weekly (clinical trial doses)
At 5 mg/mL: 24 units = 1.2 mg, 48 units = 2.4 mg
Lyophilized: -20°C; Reconstituted: 2-8°C for up to 4 weeks
| Week | Daily Dose | Units (per injection) |
|---|---|---|
| Weeks 1-4 | 0.6 mg weekly | 12 units once weekly |
| Weeks 5-8 | 1.2 mg weekly | 24 units once weekly |
| Weeks 9+ | 2.4 mg weekly | 48 units once weekly |
- 1Draw 1.0 mL bacteriostatic water with a sterile syringe
- 2Inject slowly down the vial wall
- 3Gently swirl until fully dissolved - do not shake
- 4Label with date and concentration, refrigerate immediately
Cagrilintide is an acylated amylin analog with extended half-life. Amylin slows gastric emptying, promotes satiety, and suppresses glucagon. Combined with GLP-1 agonists, it provides complementary mechanisms for weight management.
- Promotes satiety through amylin pathway
- Slows gastric emptying
- Complementary to GLP-1 agonists
- Once weekly dosing
- Novo Nordisk CagriSema clinical trial data
- Lau DCW, et al. Cagrilintide Phase 2 results. Lancet. 2021
- Amylin analog research for obesity
Lyophilized
Store at -20°C, protected from light
Reconstituted
Refrigerate at 2-8°C, use within 4 weeks
Often combined with GLP-1 agonists
- •Investigational compound - not yet approved
- •Being developed as CagriSema combination
- •May cause nausea during titration
- •Do not use with pramlintide
Disclaimer: This content is intended for research and educational purposes only. Not intended to diagnose, treat, cure, or prevent any disease. All compounds are for research use only. Dosing information is derived from published scientific literature and clinical studies.